Persistence Market Research Blog

Archive for the ‘Pharmaceuticals’ Category

Orthostatic Hypotension Market : Global Industry Analysis and Forecast 2016 – 2022

Orthostatic hypotension, also known as postural hypotension, is a state of dizziness that is caused due to low blood pressure. This is commonly happen when a person stands up from a long sitting and feel dizziness. Orthostatic hypotension can be caused due to heart problems, dehydration, endocrine problems and nervous system disorders. Also, it has been found that nursing home elderly residents are more prone to OH than people who stay living in the community. In OH, there is at least 10 mm Hg in diastolic blood pressure and 20 mm Hg fall in systolic blood pressure. Generally, OH last for few seconds to few minutes however, long lasting of OH is a sign of serious problem and one must consult with a doctor. Rate of hospitalization for OH is highly prevalent among geriatrics population.

The orthostatic hypotension disorder is mostly common in the elderly, teenagers and postpartum mothers. The key drivers that can boost the orthostatic hypotension market are increasing in the aging population with increase in the prevalence of diabetes and heart disorders along with availability of increasing number of treatments options. Increasing adoption and integration of technologies in healthcare premises along with emergence of new entrants in the existing market is expected to further propel the demand for treatment of orthostatic hypotension worldwide. Though the market is poised to witness healthy growth during the forecast period, threat of side effects with the medicines is proving a major restraint to overall growth of the market.

The Orthostatic Hypotension Market has been classified on the basis of Drug, diagnostics test and end use.

Orthostatic Hypotension Market by Drug type:

  • Fludrocortisone
  • Midodrine hydrochloride
  • Droxidopa
  • Pyridostigmine
  • Indomethacin
  • Caffeine
  • Epoetin
  • Oxilofrine potassium chloride
  • NSAIDs ( Nonsteroidal anti-inflammatory drugs)

Orthostatic Hypotension Market by Diagnostics test type:

  • ECG
  • Blood tests
  • Stress test
  • Echocardiogram

Orthostatic Hypotension Market by end use type:

  • Hospitals
  • Diagnostic centers
  • Clinics
  • Ambulatory surgical centers

Availability of variety of antihypertensive agents for the treatment of orthostatic hypotension is expected to drive the global orthostatic hypotension treatment market. Innovative treatment and diagnostic options are expected to contribute in the growth of orthostatic hypotension market in the forecast period. Among the available drugs for treatment fludrocortisone is used widely to increase the amount of fluid containing in the blood which would contribute for the increased market share of orthostatic hypotension market.

Interested in report: Please follow the below links to meet your requirements; 

Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/9653

Depending on geographic region, orthostatic hypotension market is segmented into seven key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global orthostatic hypotension market followed by Europe, Japan and Asia Pacific. The developing nations in Asia Pacific, Middle East and Africa hold huge potential for growth in the orthostatic hypotension market due to its affordable prices and number of clinical trials conducted in these regions. Also, over the period of time, there has been significant growth in terms of healthcare expenditure. Liberalization of stringent regulatory policies along with high emphasis on FDI has led to significant investment in healthcare sectors in developing regions. This in turn, is expected to boost the healthcare market in developing regions especially Asia Pacific excluding Japan (APEJ).

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/9653

Key players of orthostatic hypotension market are Mylan Inc, Upsher-Smith Laboratories, Chelsea Therapeutics, Amgen, F. Hoffman-La Roche. Apotex, Inc.

For more info: http://www.persistencemarketresearch.com/contact-us.asp

The report covers exhaustive analysis on: 

  • Orthostatic Hypotension Market Segments
  • Orthostatic Hypotension Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Orthostatic Hypotension Market Size & Forecast 2016 to 2022
  • Orthostatic Hypotension Market Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Orthostatic Hypotension Market Drivers and Restraints

Regional analysis includes 

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Follow us on: https://www.linkedin.com/company/persistence-market-research-&-consulting 

Report Highlights: 

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Browse Full PDF: Orthostatic Hypotension Market

Advertisements

Hypocalcaemia Treatment Market : Global Industry Analysis and Forecast 2016 – 2022

Hypocalcaemia is imbalance of electrolytes which is indicated by abnormally low level of calcium in the body. A healthy person has 8.5-10.2 mg/dL calcium level in his/her body, however, drop in this level could possibly led to hypocalcaemia disorder. Middle aged population needs to take 1000 mg of calcium while geriatrics population aged 65 and above should take 1500 mg of calcium per day. Hypocalcaemia is caused by hypoalbuminemia, hyperphosphatemia, surgical effects, medication effects, hypomagnesemia, heart failure, muscle cramps, vitamin D deficiency, alcoholism, magnesium deficiency, insufficient protein in the blood, in the blood and many more. Neuromuscular irritability is the most common sign of hypocalcaemia. Hypocalcaemia are mostly diagnosed by clinical suspicion and laboratory testing. Hypoparathyroidism has a major effect on hypocalcaemia and high recurrence rate. (more…)

Global Opioids Market is anticipated to exhibit a stable CAGR during the forecast period, 2015 – 2021

Persistence Market Research (PMR) delivers key insights on the Global Opioids Market in its latest report titled “Global Opioids Market is anticipated to exhibit a stable CAGR during the forecast period, 2015 – 2021”.The global opioids market is anticipated to exhibit a stable CAGR during the forecast period (2015-2021).

By product type, the global opioids market is segmented into morphine, codeine, fentanyl, meperidine and methadone. Morphine segment was the largest contributor in overall opioids market, accounting for around 36% share in 2014. However, fentanyl segment is expected to register fastest CAGR of 4.7% during the forecast period. Synthetic opioids such as fentanyl, meperidine and methadone have lucrative growth opportunities in opioids market, owing to their potential application in opioid substitution treatment and fewer side effects as compared to natural opioids. By application, the global opioids market is segmented into analgesia, cough suppression, and diarrhea suppression. Analgesia segment comprises numerous conditions namely, anesthesia, surgical pain, injury or trauma, cancer pain and pain arising from diseases. The analgesia segment accounted for around 67% share in overall opioids market in 2014 and is expected to register fastest CAGR of 3.3% during the forecast period.

Global opioids market growth is mainly driven by increasing demand for opioids in non-cancer pain management, rising geriatric populations suffering from terminal conditions, uncontrolled prescription of opioids especially in North America, and increasing healthcare expenditure for post-surgical care. Moreover, increasing the incidence of trauma injuries, raising awareness about palliative care, higher efficacy of synthetic opioids and favorable reimbursement policies for post-operative care are fueling the growth of opioids market, globally. However, chronic side effects associated with long-term consumption, limited availability of opioids in Asia Pacific, Africa and certain countries in Europe, high level of abusive consumption and growing adoption for pain-free surgeries are likely to impede the growth of global opioids market to a certain extent. Also, the over-regulated environment for the commercial use of opioids especially in developing countries such as India and China and lack of awareness for palliative care in these countries is projected to hamper the growth of the opioids market to a large extent.

Interested in report: Please follow the below links to meet your requirements; Request for the Report Sample: http://www.persistencemarketresearch.com/samples/3066

North America and Europe have been estimated to collectively account for over 85% revenue share of the total opioids market in 2015. Asia-Pacific is projected to be the fastest-growing market, owing to increasing awareness for cancer pain management, a presence of large patient pool suffering from terminal conditions and reformed regulatory guidelines for the prescription of opioids.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/3066

Global opioids market report begins with an overview of the global opioids market in terms of value. This section includes the detailed analysis of key trends, drivers and restraints, and opportunities, which are the main factors impelling growth of the opioids market. Impact analysis of key growth drivers and restraints based on the weighted average of each one of these factors in model-based approach is included in the opioids market report. The report provides a scrutinized information on the potential scope of Abuse Deterrent Formulations (ADF) with the help of pipeline analysis to better equip clients with crystal clear decision-making insights.

For more info: http://www.persistencemarketresearch.com/contact-us.asp

Key players operating in the global opioid market include Pfizer Inc., Purdue Pharma, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc., Actavis Plc., Sanofi, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc. and Egalet. Companies are majorly focusing on the development of abuse-deterrent formulations, owing to increased abusive consumption of opioids. Companies are also collaborating with local manufacturers to gain maximum market share from their generic products.

 

Recurrent Glioblastoma Multiforme (GBM) Treatment Market : Global Industry Analysis and Forecast 2016 – 2022

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumor in humans that involves glial cells. GBM is present in two variants namely, giant cell glioblastoma and gliosarcoma. Gliomas are tumors arising from glial cells and may occur in the spinal cord or the brain, the latter being more common. Gliomas are the most common type of brain tumor and can be either supratentorial or infratentorial.  Seizure, nausea, headache, hemiparesis and memory loss are some of the common symptoms observed in the patients suffering from GBM. GBM is most commonly found in male with the age of 65 years and above.

Alcohol consumption and malaria are the possible risk factors for the development of GBM. In addition, neurofibromatosis, tuberous sclerosis, von-hippel-lindau disease, Li-fraumeni syndrome and turcot syndrome are some of the genetic disorders that are associated with increasing incidences of gliomas. Glioblastoma multiforme is a World Health Organization Grade IV tumor that represents 15 to 20% of all primary intracranial tumors.

Increasing habits of alcohol consumption, changing lifestyle and increasing incidence of seizure are some of the drivers for the growth of GBM market. GBM is generally treated by first surgically removing the tumor then treating with chemotherapy and radiation. While this treatment plan is the currently accepted standard of care, it does not effectively prevent tumor recurrence, which ultimately causes death in GBM patients. This factor is expected to be the prime restraint for the growth of recurrent glioblastoma multiforme market.

Recurrent Glioblastoma Multiforme (GBM) market is segmented on the basis of treatment, end user and geography.

Based on treatment, GBM market can be segmented as follows:

  • Oral Medications
  • Temozolomide
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Radiation therapy
  • Chemotherapy

Based on end user, GBM market can be segmented as follows:

  • Hospitals
  • Clinics
  • Ambulatory surgical centers

Primary treatment involves surgery to achieve tumor debulking, followed by a multimodal regimen of radiotherapy and chemotherapy. Chemotherapy can be added to radiotherapy for patients with unfavorable low-grade glioma to improve progression free survival. The most frequently used chemotherapy regimens are a combination of procarbazine, lomustine and vincristine, or single-agent treatment with carmustine or lomustine. Temozolomide is recommended by NICE as an option for the treatment of newly diagnosed GBM. Concomitant and adjuvant chemotherapy with temozolomide given during and after radiotherapy improves survival. This drug used along with chemotherapy or radiotherapy has led to the growth of GBM treatment market to a great extent.

Interested in report: Please follow the below links to meet your requirements; 

Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/10112

Region wise, the global recurrent glioblastoma multiforme (GBM) market is classified into regions namely, North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe dominates the global GBM market owing to rising awareness, population aging, changing lifestyle and increasing healthcare awareness accentuates the growth of GBM market in these regions. In addition, Asia-Pacific region is expected to be an emerging market due to increasing demand for better healthcare facilities.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/10112

Some of the companies competing in recurrent glioblastoma multiforme (GBM) treatment market are Astrazeneca, F. Hoffman-La Roche, Ltd., GlaxoSmithKline plc., Merck & Co., Inc., Pfizer, Inc., AngioChem, Inc. Vascular Biogeneics and others.

For more info: http://www.persistencemarketresearch.com/contact-us.asp

The report covers exhaustive analysis on:

  • Recurrent Glioblastoma Multiforme (GBM) Treatment Market Segments
  • Recurrent Glioblastoma Multiforme (GBM) Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Recurrent Glioblastoma Multiforme (GBM) Treatment Market Size & Forecast 2016 to 2022
  • Recurrent Glioblastoma Multiforme (GBM) Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Recurrent Glioblastoma Multiforme (GBM) Treatment Drivers and Restraints

Follow us on: https://www.linkedin.com/company/persistence-market-research-&-consulting

Regional analysis includes

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights: 

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Browse Full PDF: Recurrent Glioblastoma Multiforme (GBM) Treatment Market

Liposarcoma Treatment Market : Global Industry Analysis and Forecast 2016 – 2022

Liposarcoma is a cancer of fat cells lying deep within the soft tissues, typically in retroperitoneum or thighs. According to WHO, liposarcoma is the most common type of sarcomas (cancer of soft tissue) and accounts for approximately 17-20% of all cases of sarcoma. However, WHO classifies liposarcoma in the rare diseases as the incidence rate of the disease is as low as 2.5 per Mn population. Liposarcoma most commonly occurs in the middle age or adults above the age of 40 and it can be well diagnosed with the help of excision biopsy. Liposarcoma can be of four types viz. well differentiated liposarcoma, myxoid liposarcoma, pleomorphic liposarcoma and dedifferentiated liposarcoma. The most common drugs used for the treatment of liposarcoma include ifosfamide and doxorubicin. Ifosfamide is often prescribed in combination with uromitexan in order to prevent bladder irritation and internal bleeding. Moreover, cisplatin, vincristine, etoposide, gemcitabine, docetaxel etc. can be used to prevent the recurrence of liposarcoma.

The market for liposarcoma is highly fragmented with large number of generic manufacturers. The global market for liposarcoma treatment is expected to grow moderately over the forecast period owing to low incidence rate of the disease. Some other factors which are anticipated to influence growth of global liposarcoma treatment market include lifestyle changes, incidence of genetic disorders, growing awareness through liposarcoma genome project etc. However, high cost of the treatment can be the major restraint for the growth of global liposarcoma treatment market.

The global liposarcoma treatment market has been classified on the basis of treatment type, end user and geography.

Based on treatment type, the global liposarcoma treatment market is divided into following:

  • Chemotherapy
  • Radiation Therapy
  • Surgical Therapy

Based on the end user type, the global liposarcoma treatment market is divided into following:

  • Hospitals
  • Multispecialty Clinics
  • Cancer treatment and rehabilitation centers

Surgical therapy treatment segment is expected to account for major share in global liposarcoma treatment market as it is the choice of treatment recommended by majority of cancer specialists. Most of the physicians do not rely on chemotherapy for the liposarcoma treatment however, it can be used prior to the surgery to reduce the size of the tumor making it the second largest segment in terms of value in global liposarcoma treatment market. Radiation therapy treatment is used to avoid recurrence of the liposarcoma after surgery and contributes a minimal share in global liposarcoma treatment market.

Interested in report: Please follow the below links to meet your requirements; 

Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/10109

Geographically, global liposarcoma treatment market is classified into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is anticipated to lead the global liposarcoma treatment market due to relatively greater prevalence of the disease in the region. APAC and MEA regions are expected to witness steady market growth owing to lack of awareness about the disease.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/10109

Some of the key players in global liposarcoma treatment market include Eli Lilly and Company, Baxter International, Bristol Laboratories Ltd., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Actavis plc.,Fresenius Kabi Ltd., Accord Healthcare Inc., Taro Pharmaceuticals Inc., Sandoz, Bedford Laboratories  and others. Recently FDA approved the new indication of Halaven (eribulin) to Esai Co. Ltd. and new drug application of Yondelis (Trabectedin) from Johnson & Johnson Private Limited for use in Europe, Russia and South Korea.

For more info: http://www.persistencemarketresearch.com/contact-us.asp

The report covers exhaustive analysis on:

  • Liposarcoma Treatment Market Segments
  • Liposarcoma Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Liposarcoma Treatment Market Size & Forecast 2016 to 2022
  • Liposarcoma Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Liposarcoma Treatment Drivers and Restraints

Follow us on: https://www.linkedin.com/company/persistence-market-research-&-consulting 

Regional analysis includes 

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Report Highlights: 

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Eye infections treatment Market : Global Industry Analysis and Forecast 2016 – 2022

Various viruses, bacteria, parasites, and fungi that can invade the human body are also potential of attacking the surface or interior of the eye. Eye infections can be the inflammation of the Conjunctiva (Conjunctivitis), eyelid (blepharitis), the cornea (keratitis), the liquid inside the eye (vitritis), the retina and the blood vessels that feed it (chorioretinitis), or the optic nerve (neuroretinitis). The most common cause of eye infection is conjunctivitis caused by adenovirus, other cause of conjunctivitis is bacteria such as staphylococcus aureus and is common in children. Infection that can cause conjunctivitis or keratitis included syphilis, gonorrhea, chlamydia, herpes simplex, hepatitis B, tuberculosis, leprosy, lyme disease, mumps, measles, influenza & mycosis etc. The infection that can damage the retina and the inner eye includes few of the bacteria discussed above including syphilis, tuberculosis, toxoplasmosis, sarcoidosis, herpes simplex, varicella zoster, histoplasmosis, gonorrhea etc. The symptom related to eye infection includes redness & itching, discharge, crusting over eyelid, pain, photosentivity, tears, swollen eyelid & involuntary blinking. Eye infection drug are grouped in following classes based on how they work: (more…)

Indolent Lymphoma Treatment Market : Global Industry Analysis and Forecast 2016 – 2022

Indolent Lymphoma also known as non-Hodgkin’s lymphoma is a type of cancer that initiates from cells of immune system which are responsible to fight against infections and diseases encountered by our body. Lymphatic system is a part of the immune system and has network of lymph vessels in the body thus lymphoma can initiate anywhere. The factors which can cause indolent lymphoma include weak immune system, infections, age and obesity. The treatment for indolent lymphoma depends upon its stage, age and various other factors. The survival rate will again depend on the stage of the lymphoma but by treating them there is 90% in Europe. The improvements in the treatment of indolent lymphoma is also done through clinical trials to prevent and treat lymphoma and fuel the research.

Indolent lymphoma treatment is most common cancer observed in the lymphatic system and can be treated successfully. The factors which contribute to drive the indolent lymphoma market are geriatric population and lifestyle. In today’s world people have addictions to alcohol, tobacco and drugs, obesity is one of the major cause of various disorders thus the risks for such disorders are high. The mortality ratio is quite low as compared to treatment facilities available a few years back. Clinical approvals and safety regulations laid by FDA and regulatory bodies are some restraints for this market, but many other drugs are into clinical trials and will soon be available for use.

Indolent lymphoma treatment market is classified on the basis of product type and distribution channel.

Based on product type, the global indolent lymphoma treatment market is segmented into the following:

  • DNA-Damaging Drug
  • Antitumor Antibiotics
  • Antimetabolites
  • Protease Inhibitor Drug
  • Drugs preventing division of cells by blocking mitosis
  • Hormones killing Lymphocytes
  • Immunotherapy
  • Histone Deacetylase Inhibitor
  • Retinoid
  • Combination Drugs

Based on distribution channel, the global indolent lymphoma treatment market is segmented into the following:

  • Manufacturers
  • Distributors
  • Pharmacies
  • Cancer Associations

Indolent Lymphoma is fifth common type of cancer in the U.S. and there have been many advancements in its treatment. The biological treatment including the use of monoclonal bodies have accelerated the research of indolent lymphoma treatment. There are about 70000 incidence cases observed every year in the U.S. and are successfully treated according to the stages of the lymphoma. Immunotherapy has also led to a dramatic improvement in its prognosis, radioimmunotherapy and many other therapies have proven to decrease the mortality rate in many regions as the U.S. and Europe. Chemotherapy and biological therapies also clinical trials have been most widely used to treat indolent lymphoma.

Interested in report: Please follow the below links to meet your requirements; 

Request for the Report Brochure: http://www.persistencemarketresearch.com/samples/10040

Geographically, the market for indolent lymphoma treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Over the past few years there have been low incidence rates since there was almost an epidemic in the U.S. in the early 90’s. But compared to the previous epidemic outbreak the market for indolent lymphoma treatment is still high in North America. Considering the overall lymphoma treatment market the U.S. and Western Europe account for 40% of the lymphoma diagnosed cases. The aging population in this regions is more and thus all the other related lifestyle risks are associated to accelerate the treatment process of indolent lymphoma. Some of the cancer associations have taken major step towards treating it by introducing clinical trial processes.

Request TOC (table of content), Figures and Tables of the Report: http://www.persistencemarketresearch.com/toc/10040

Some of the market players in indolent lymphoma treatment include F. Hoffmann-La Roche Ltd, Bayer AG, Gilead Sciences, Spectrum Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Celgene Corporation, Sanofi S.A. and GlaxoSmithKline plc.

For more info: http://www.persistencemarketresearch.com/contact-us.asp

The report covers exhaustive analysis on: 

  • Indolent Lymphoma Treatment Market Segments
  • Indolent Lymphoma Treatment Market Dynamics
  • Historical Actual Market Size, 2013 – 2015
  • Indolent Lymphoma Treatment Market Size & Forecast 2016 to 2022
  • Indolent Lymphoma Treatment Current Trends/Issues/Challenges
  • Competition & Companies involved
  • Indolent Lymphoma Treatment Drivers and Restraints

Regional analysis includes 

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Follow us on: https://www.linkedin.com/company/persistence-market-research-&-consulting 

Report Highlights:

  • Shifting Industry dynamics
  • In-depth market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies of key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Browse full PDF: Indolent Lymphoma Treatment Market

Tag Cloud